


TXNIP DNA methylation is associated with glycemic control over 28 years in type 1 diabetes: findings from the Pittsburgh Epidemiology of Diabetes Complications (EDC) study

Rachel G Miller ¹, Josyf C Mychaleckyj,² Suna Onengut-Gumuscu,² Trevor J Orchard,¹ Tina Costacou¹

To cite: Miller RG, Mychaleckyj JC, Onengut-Gumuscu S, *et al.* TXNIP DNA methylation is associated with glycemic control over 28 years in type 1 diabetes: findings from the Pittsburgh Epidemiology of Diabetes Complications (EDC) study. *BMJ Open Diab Res Care* 2023;**11**:e003068. doi:10.1136/bmjdc-2022-003068

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjdc-2022-003068>).

Received 28 July 2022
Accepted 21 December 2022



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
²Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA

Correspondence to
Dr Rachel G Miller;
MillerR@edc.pitt.edu

ABSTRACT

Introduction DNA methylation (DNAm) has been cross-sectionally associated with type 2 diabetes and hemoglobin A1c (HbA1c) in the general population. However, longitudinal data and data in type 1 diabetes are currently very limited. Thus, we performed an epigenome-wide association study (EWAS) in an observational type 1 diabetes cohort to identify loci with DNAm associated with concurrent and future HbA1cs, as well as other clinical risk factors, over 28 years.

Research design and methods Whole blood DNAm in 683 597 CpGs was analyzed in the Pittsburgh Epidemiology of Diabetes Complications study of childhood onset (<17 years) type 1 diabetes (n=411). An EWAS of DNAm beta values and concurrent HbA1c was performed using linear models adjusted for diabetes duration, sex, pack years of smoking, estimated cell type composition variables, and technical/batch covariates. A longitudinal EWAS of subsequent repeated HbA1c measures was performed using mixed models. We further identified methylation quantitative trait loci (meQTLs) for significant CpGs and conducted a Mendelian randomization.

Results DNAm at cg19693031 (Chr 1, *Thioredoxin-Interacting Protein (TXNIP)*) and cg21534330 (Chr 17, *Casein Kinase 1 Isoform Delta*) was significantly inversely associated with concurrent HbA1c. In longitudinal analyses, hypomethylation of cg19693031 was associated with consistently higher HbA1c over 28 years, and with higher triglycerides, pulse rate, and albumin:creatinine ratio (ACR) independently of HbA1c. We further identified 34 meQTLs in *SLC2A1/SLC2A1-AS1* significantly associated with cg19693031 DNAm.

Conclusions Our results extend prior findings that TXNIP hypomethylation relates to worse glycemic control in type 1 diabetes by demonstrating the association persists over the long term. Additionally, the associations with triglycerides, pulse rate, and ACR suggest TXNIP DNAm could play a role in vascular damage independent of HbA1c. These findings strengthen potential for interventions targeting TXNIP to improve glycemic control in type 1 diabetes through its role in *SLC2A1*/glucose transporter 1-mediated glucose regulation.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Methylation at the Thioredoxin-Interacting Protein (TXNIP) locus has been consistently associated with concurrent glycemia and type 2 diabetes in the general population, but long-term data and data in type 1 diabetes are limited.

WHAT THIS STUDY ADDS

⇒ Examining HbA1c over the subsequent 28 years after methylation measurement, we demonstrate that hypomethylation at TXNIP is associated with worse long-term glycemic control and with higher triglycerides, pulse rate, and albumin:creatinine ratio independent of HbA1c.
⇒ We observed that TXNIP methylation is influenced by variants in *SLC2A1*, the gene encoding glucose transporter 1, for the first time in type 1 diabetes.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ These results support a role for TXNIP methylation in long-term glycemic control and vascular health and as a promising target for potential adjunctive therapies to insulin in type 1 diabetes.

INTRODUCTION

Intensive insulin therapy is critical for preventing complications of type 1 diabetes.¹ However, insulin therapy carries its own risks of adverse consequences, most notably hypoglycemia and weight gain. Additionally, despite improvements in insulin analogues and delivery systems, current insulins do not adequately mimic a physiological insulin response.² Thus, there remains a need to identify new targets for adjunctive therapies to insulin to reduce its adverse effects and improve blood glucose control and stability in type 1 diabetes.

Epigenetic modifications to DNA, including methylation (DNA methylation (DNAm)), are affected by environmental exposures and influence gene expression. DNAm at 5'-cytosine-phosphate-guanine-3' (CpG) sites is currently the most studied epigenetic modification due to its relative affordability and ease of measurement. DNAm provides a link between genetic susceptibility and risk factor exposure and has potential to be pharmacologically modified³; thus, its study may elucidate novel pathophysiological pathways and intervention targets. DNAm at the *Thioredoxin-Interacting Protein* (*TXNIP*) locus has consistently been associated with cross-sectional type 2 diabetes status and HbA1c in a rapidly accumulating body of general population studies; however, prospective data are lacking.⁴⁻¹⁴ In type 1 diabetes, the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study recently demonstrated a strong association between hemoglobin A1c (HbA1c) during the DCCT randomized trial period and cg19693031 DNAm in *TXNIP*.¹⁵ However, DCCT excluded individuals with high blood pressure, cholesterol, or more than minimal retinopathy or albuminuria at baseline,¹⁶ so it is unclear if their findings apply to populations without risk factor or advanced microvascular complication exclusion. Therefore, given the limited understanding of the relationship between DNAm and glycemia both in general and in type 1 diabetes, we performed an epigenome-wide association study (EWAS) of DNAm and HbA1c in an observational type 1e diabetes cohort, the Pittsburgh Epidemiology of Diabetes Complications (EDC) study, aiming to identify loci with DNAm associated with concurrent HbA1c and future HbA1c over 28 years.

RESEARCH DESIGN AND METHODS

Study population

The Pittsburgh EDC study is a prospective cohort study of childhood-onset (<17 years old) type 1 diabetes, which has been described in detail.¹⁷ All participants (n=658) were diagnosed with type 1 diabetes, or seen within 1 year of diagnosis, at Children's Hospital of Pittsburgh between 1950 and 1980. Participants were followed up beginning in 1986–1988, with biennial examinations and questionnaires for the first 10 years and thereafter with biennial questionnaires and further examinations in 2004–2006, 2011–2013, and 2016–2018. DNA was collected at study visits between 1988 and 1998: 86% of the DNA specimens were collected at the 1988–1990 visit, 9% at the 1990–1992 visit, and the remaining 5% between 1992 and 1998. The date of each participant's DNA specimen defines their baseline for these analyses.

DNA methylation (DNAm) arrays, quality control, and data processing

High-molecular weight DNA was isolated from whole blood-derived leukocytes.¹⁸ DNA specimens with adequate concentration (>30 ng/ μ L) and volume (>25

μ L) were deemed eligible for DNAm assessment. Specimens were randomly assigned to plate and well position. DNAm was assayed using Illumina Infinium MethylationEPIC BeadChip arrays (Illumina, San Diego, California, USA) at the University of Virginia Center for Public Health Genomics, Genomic Sciences Lab using the standard Illumina methylation array protocol. The technical specifications and validation of the Infinium MethylationEPIC BeadChip have been described in detail.¹⁹ The detailed quality control and data processing pipeline is described in the online supplemental materials. Briefly, quality control used methods implemented in two R packages, *minfi*²⁰ and *SeSAMe*.²¹ The final methylation fraction β values for analysis were generated using the following pipeline steps in *SeSAMe*²¹: (1) background subtraction based on normal-exponential deconvolution using out of band probes (noob), (2) dye bias correction in the two color channels through non-linear scaling (dyeBiasCorrTypeINorm), (3) probe quality masking based on the curated exclusion list²² (qualityMask), (4) detection masking at individual probe/sample level using *pooBAH* p value out of band array hybridization (detectionMask), (5) beta calculation, M/M+U (getBetas), and (6) drop samples and probes identified during quality control preprocessing. Of the original 865 918 probes on the array, we dropped a curated exclusion list of 95 923²² and an additional incremental set of 72 868 poor quality probes that had detection rate of <95% in all samples. We further restricted analysis to probes mapped to autosomal chromosomes; thus, 683 597 probes were analyzed.

Online supplemental figure 1 summarizes the sample quality control results and resulting analytical data set. Of 496 participants who consented to DNA collection, 436 European ancestry participants had suitable quality DNA remaining in 2020 for methylation arrays. After excluding participants not passing methylation quality control (n=11), 1 randomly selected individual from each of 10 first-degree relative pairs, 2 outliers from a previous genetic principal components analysis based on GWAS data²³ and 2 duplicate specimens, the final sample with quality methylation data comprised 411 participants.

As the DNA was isolated from whole blood, variable cell-type composition could confound tests of association with outcomes.²⁴ Thus, cell-type compositions (CD8+ T cells, CD4+ T cells, natural killer cells, B cells, monocytes, and neutrophils) were estimated for inclusion as covariates in statistical models using the *estimateCellCounts2* function from the R package *FlowSorted.Blood.EPIC*²⁵ with an IDOL-optimized probe set²⁶ derived from the original Houseman method,²⁷ which has been shown to be an optimal algorithm for cell-type deconvolution in EWAS using whole blood specimens.²⁴ Gene information was obtained from Illumina annotation (March 2020, reference genome GRCh38/hg38).

Glycosylated hemoglobin

HbA1 was measured at five visits (1988–1990, 1990–1992, 1992–1994, 1994–1996, and 1996–1998); HbA1c was

measured at three visits (2004–2006, 2011–2013, and 2016–2018). The median number of measures was six per participant. From 1988 to 1998, HbA1c was measured using automated high-performance liquid chromatography (Diamat; Bio-Rad, Hercules, California, USA) and converted to DCCT-aligned HbA1c values using a validated regression equation derived from duplicate assays (DCCT HbA1c=0.14+0.83 (EDC HbA1c)).²⁸ At the 2004–2006, 2011–2013, and 2016–2018 visits, HbA1c was measured using the DCA 2000 analyzer (Bayer Healthcare LLC, Elkhart, Indiana, USA) and converted to DCCT-aligned HbA1c with the equation: DCCT HbA1c=(EDC HbA1c–1.13)/0.81.²⁸

Statistical analysis

Epigenome-wide associations and post hoc analyses of significant CpGs

We used linear regression to estimate the cross-sectional association between DNAm probe β value at each CpG site as the dependent variable and baseline HbA1c as the primary independent variable. Three models were fit: model 1 included HbA1c, type 1 diabetes duration, sex, pack years of smoking, estimated cell-type composition variables, plate/run indicator, well position, Green CpC to TpC (GCT) bisulfite score, DNA extraction method, and study visit of DNA collection; model 2 included model 1+first two ancestry principal components from genotyping arrays; and model 3 included model 2+two surrogate variables estimated using the *sva* function of the *SVA* package in R²⁹ to account for potential latent sources of variation in addition to the covariates directly adjusted for in model 1. As EDC is an exclusively childhood-onset type 1 diabetes cohort, age and diabetes duration are highly correlated ($r=0.86$, $p<0.0001$). Given the aims of our analyses, diabetes duration better reflects the exposure of interest; thus, the results presented here were adjusted for diabetes duration only. However, alternative models were fit, adjusting for age instead of diabetes duration, and results were nearly identical. We applied a Bonferroni-corrected significance level of $p<7.31\times 10^{-8}$ ($p=0.05/683$ 597 CpGs) to determine conservative statistical significance. We also identified CpGs nominally associated with HbA1c using a Benjamini-Hochberg false discovery rate (FDR) of $<20\%$. As the conventional genomic inflation factor λ has been shown to overestimate test statistic inflation in EWAS,³⁰ we also report the Bayesian inflation factor estimated using the *bacon* method (*λ .bacon*) developed by van Iterson *et al* specifically for EWAS.³⁰ In sensitivity analyses to assess the impact of extreme methylation beta values, we repeated analysis of all significant CpGs using robust linear regression.

We performed a second EWAS for longitudinal HbA1c using all available measures over the subsequent 28-year follow-up period. Linear mixed-effects models of the form

$$y_{st} = \beta_0 + S_{os} + \beta_{cpG} X_{cpG} + \beta_1 X_1 + \dots + \beta_j X_j + e_{st}$$

were fit for each CpG probe, where y is the postbaseline longitudinal HbA1c for subject s at time t ; S_{os} is the subject-specific random intercept offset, and e_{st} is the subject-specific error term. Models were adjusted for baseline HbA1c and covariates included in the Model 3 adjustment described above (denoted as $b_j X_j$ through $b_j X_j$ in the equation). Model residuals were plotted and visually examined to assess fit.

We assessed whether HbA1c-associated CpGs were associated with other clinical characteristics independent of HbA1c. Details regarding ascertainment of clinical variables have been published previously³¹ and are summarized in the online supplemental materials. For CpGs associated with baseline HbA1c, cross-sectional associations with other clinical variables were modeled individually using linear regression with the clinical factor as the independent variable and methylation β as the dependent variable, adjusting for type 1 diabetes duration, sex, HbA1c, pack years of smoking, and cell-type composition variables. Clinical variables with p values of <0.20 in the individual models were offered to fit a multivariable model using backward selection. Variables with $p<0.10$ were retained in the final model. For CpGs associated with subsequent longitudinal HbA1c, associations with other longitudinal clinical factors were assessed using linear mixed models with baseline DNAm quartile as the main independent variable and each longitudinal clinical factor as the dependent variable in separate models of the form shown previously. Models were adjusted for time-varying HbA1c, sex, and baseline diabetes duration, pack years of smoking, and cell-type composition variables. Time \times DNAm quartile interaction term was used to estimate change in the DNAm–clinical factor association over time.

Identification of methylation quantitative trait loci (meQTLs)

Genotyping was performed in $n=453$ EDC participants using the Infinium HumanCore Exome-24 BeadChip (Illumina), following the manufacturer's protocol. As previously described,³² after quality control and exclusions, quality genotyping data were available for a total of $n=422$. Minimac3/Minimac3 omp V.1.0.14 was used for imputation, with the 1000 Genomes (1 kg) phase 3 V.5 reference panel (updated October 20, 2015). To identify potential meQTLs, we performed a GWAS for each CpG that was significantly associated with HbA1c in the $n=411$ with available methylation data. In each GWAS, methylation β values were modeled as the dependent variable and single nucleotide polymorphism (SNP) dosage (additive coding) as independent variables in separate linear models, adjusting for sex, type 1 diabetes duration, the first three ancestry principal components, and estimated cell type composition variables. SNPs with $p<5\times 10^{-8}$ were identified as meQTLs for the corresponding CpG. Results were compared with the Genetics of DNA Methylation Consortium (GoDMC) database of meQTLs³³ for external validation. We examined the overlap between significant meQTLs and expression

quantitative trait loci (eQTLs) reported in the Genotype-Tissue Expression (GTEx) project. GTEx was supported by the Common Fund of the Office of the Director of the National Institutes of Health and by the National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), and National Institute of Neurological Disorders and Stroke (NINDS). The data used here were obtained from the GTEx Portal on February 25, 2022. Plots of the meQTL genomic regions were made using LocusZoom.³⁴

Mendelian randomization

We used two-sample Mendelian randomization to examine a potential causal association between DNAm and HbA1c for CpGs with significant meQTLs. Analyses were performed using the MR-Base R package *TwoSampleMR* V.0.5.6.³⁵ Using the *clump_data* function with the default $r^2=0.001$, we identified independent representative SNPs from the set of GoDMC meQTLs to use as the instrumental variable (IV). The estimated association between the IV and HbA1c was obtained using summary data from the Meta-Analysis of Glucose and Insulin-related traits Consortium,³⁶ comprising 46 368 individuals of European descent, via the IEU Open GWAS Project database.³⁵ The causal effect between DNAm and HbA1c was estimated using the Wald ratio.

RESULTS

Differential methylation and HbA1c cross-sectional EWAS

Baseline characteristics are shown in online supplemental table 1. A Manhattan plot for the cross-sectional EWAS with baseline HbA1c (final model 3 adjustment) is in figure 1. Methylation at two CpGs (cg19693031 in *TXNIP* on chromosome 1 and cg21534330 in *Casein Kinase 1 Isoform Delta (CSNK1D)* on chromosome 17) were significantly, inversely associated with cross-sectional baseline HbA1c (table 1). Results were nearly identical for model 1 and model 2 adjustments (data not shown). QQ plots for the three models are shown in online supplemental figure 2. The traditional genomic inflation factor showed some evidence of inflation ($\lambda_{\text{model1}}=1.33$, $\lambda_{\text{model2}}=1.26$, $\lambda_{\text{model3}}=1.30$), but *bacon*-estimated inflation factors were close to 1 (*bacon* $\lambda_{\text{bacon-model1}}=1.09$, $\lambda_{\text{bacon-model2}}=0.97$, $\lambda_{\text{bacon-model3}}=0.92$); thus, *bacon*-estimated FDRs are shown in table 1.

Methylation β -value distributions for cg19693031 and cg21534330 are shown in online supplemental figure 3. Further examination of the model residuals for cg21534330 (online supplemental figure 4) showed five participants with extreme methylation β values. Scatter plots of cg19693031 and cg21534330 methylation β values by HbA1c are shown in online supplemental figure 5. Four of the five participants with extreme cg21534330 methylation β values also had HbA1c >95th percentile




Figure 1 Manhattan plot of epigenome-wide associations of DNA methylation with baseline HbA1c in the Epidemiology of Diabetes Complications cohort and gene track plots for significant 5'-cytosine-phosphate-guanine-3's. (A) Manhattan plot; the red line marks the epigenome-wide significance level $p < 7.31 \times 10^{-8}$; the blue line marks the suggestive significance level corresponding to false discovery rate of $< 20\%$. (B) Ideogram and gene track plot for the *TXNIP* region of chromosome 1 with cg19693031 annotated in red. (C) Ideogram and gene track plot for the *CSNK1D* region of chromosome 17 with cg21534330 annotated in red. *TXNIP*, Thioredoxin-Interacting Protein. *CSNK1D*, Casein Kinase 1 Isoform Delta.

Table 1 CpGs associated with cross-sectional HbA1c at FDR of <20% in the EDC study

ID	Chr	Location	CpG position	Gene symbol	Location relative to gene	β per 1% HbA1c	SE	P value	bacon-adjusted FDR*
cg19693031	1	Open Sea	145 441 552	<i>TXNIP</i>	3'UTR	-0.016	0.0025	2.67E-10	0.0001
cg21534330	17	S. Shore	80 209 281	<i>CSNK1D</i>	Body	-0.009	0.0014	1.15E-09	0.0001
cg21857724	2	Open Sea	231 523 609	n/a	Intergenic	-0.005	0.0010	3.31E-07	0.0462
cg03827739	10	Open Sea	75 401 754	<i>MYOZ1</i>	TSS1500	0.004	0.0007	8.69E-07	0.1506
cg14209562	5	Open Sea	177 880 534	<i>COL23A1</i>	Body	-0.006	0.0013	8.93E-07	0.0800
cg19225602	11	N.Shelf	75 269 316	n/a	Intergenic	-0.003	0.0007	2.18E-06	0.0800
cg27629986	2	Open Sea	219 585 157	<i>TLL4</i>	5'UTR	-0.003	0.0007	2.23E-06	0.1320
cg06053844	6	Open Sea	3 870 115	n/a	Intergenic	-0.003	0.0007	2.83E-06	0.1320
cg24236935	2	Open Sea	20 690 701	n/a	Intergenic	-0.004	0.0009	3.07E-06	0.1320
cg18422654	14	Open Sea	23 905 273	<i>MYH7</i>	TSS1500	-0.003	0.0006	3.40E-06	0.1325
cg11069395	12	N.Shore	53 272 002	n/a	Intergenic	-0.004	0.0008	3.59E-06	0.1325
cg21513463	12	Open Sea	131 076 481	n/a	Intergenic	-0.002	0.0004	3.80E-06	0.1325
cg17238830	5	Open Sea	76 256 017	<i>CRHBP</i>	Body	-0.005	0.0011	4.34E-06	0.1325
cg14051336	5	S.Shelf	149 515 317	<i>PDGFRB</i>	Body	-0.004	0.0008	4.83E-06	0.1325
cg03167712	6	Open Sea	83 587 490	n/a	Intergenic	-0.005	0.0010	5.71E-06	0.1325
cg18640098	5	Open Sea	9 888 660	<i>LOC285692</i>	Body	-0.004	0.0009	9.60E-06	0.1325
cg09847325	1	Open Sea	4 842 442	<i>AJAP1</i>	3'UTR	-0.004	0.0009	1.04E-05	0.1339
cg09905117	19	Open Sea	47 454 619	<i>ARHGAP35</i>	Body	-0.004	0.0009	1.05E-05	0.1410
cg03156851	13	Open Sea	88 675 293	n/a	Intergenic	-0.006	0.0013	1.15E-05	0.1506

Results of linear models adjusted for type 1 diabetes duration, sex, pack years of smoking, estimated cell type composition variables, and plate/run indicator, well position, GCT bisulfite score, DNA extraction method, study visit of DNA collection, first two principal components of ancestry from genotyping arrays, and two surrogate variables from *sva*, sorted by ascending p value.

*Bolted rows are significant at the Bonferroni-adjusted threshold, $p < 7.3 \times 10^{-8}$.

CpG, 5'-cytosine-phosphate-guanine-3'; *CSNK1D*, *Casein Kinase 1 Isoform Delta*; EDC, Epidemiology of Diabetes Complications; FDR, false discovery rate; n/a, not applicable; *TXNIP*, *Thioredoxin-Interacting Protein*.

for the cohort (ie, >12.3% (111 mmol/mol)), suggesting they may represent biological extremes. To assess the impact of these extreme values, we repeated the analysis of cg21534330 and HbA1c using robust linear regression and observed attenuation of the association (regression $\beta \pm \text{SE} = -0.0017 \pm 0.0006$, $p = 0.0034$). Of the other CpGs with an FDR of <20%, results were unchanged after repeating the analysis using robust linear regression, except for cg17238830 ($\beta = -0.0021 \pm 0.0007$, $p = 0.0012$) and cg03167712 ($\beta = -0.0030 \pm 0.0008$, $p = 0.0001$).

Differential methylation and longitudinal HbA1c EWAS

In a longitudinal EWAS, methylation of cg19693031 in *TXNIP* was significantly inversely associated with HbA1c, such that each 5% greater methylation at baseline was associated with -0.20 ($\text{SE} = 0.03$) lower mean HbA1c over 28 years (table 2). Methylation at 11 other CpGs had suggestive associations with longitudinal HbA1c at an FDR of <20%, including two additional CpGs in *TXNIP* (cg02988288, *bacon* FDR=0.03; cg26974062, *bacon* FDR=0.18). Plots of residuals did not suggest evidence of poor fit or influential observations. Figure 2 shows longitudinal HbA1c by quartiles of cg19693031 methylation. There was no evidence that the association between cg19693031 methylation and HbA1c changed over time (methylation \times time interaction $p = 0.30$).

Methylation quantitative trait loci

Thirty-four variants in linkage disequilibrium (LD) in *SLC2A1* (1p34.2), the gene encoding glucose transporter 1 (GLUT1), and *SLC2A1-AS1* were significantly associated with cg19693031 methylation, as were two variants in *ADRA1A* (8p21.2) (online supplemental figure 6 and online supplemental table 2). Locus zoom plots for the respective genomic regions are shown in online supplemental figure 7. The same 34 *SLC2A1/SLC2A1-AS1* variants were also significant meQTLs for cg19693031 in the GoDMC database, along with an additional 114 variants (95 SNPs and 19 insertion–deletion mutations) in the same genomic region (data accessed February 25, 2022). Of the 34 cg19693031 meQTLs identified in *SLC2A1/SLC2A1-AS1*, 32 were also reported to be whole blood eQTLs in GTEx (data accessed February 25, 2022). There were 15 meQTLs identified for cg21534330 (*CSNK1D*) in the EDC cohort (online supplemental table 3); however, none were meQTLs for cg21534330 in GoDMC.

Mendelian randomization

Using the cg19693031 meQTLs, we performed two-sample magnetic resonance (MR) to assess a potential causal association between cg19693031 DNAm and HbA1c. Of the 129 SNPs that were meQTLs for cg19693031 in GoDMC, rs12718444 was selected as the representative SNP for the LD block after clumping and used as the IV. There was no evidence of a causal effect of cg19693031 on HbA1c ($\beta = 0.0085 \pm 0.0091$, $p = 0.351$). In further exploratory analyses in EDC, there was no association between rs12718444 and HbA1c (β per T

allele = 0.016 ± 0.144 , $p = 0.911$) and no evidence of interaction between rs12718444 genotype and cg19693031 DNAm with respect to HbA1c (interaction $p = 0.920$) in EDC.

TXNIP methylation and other clinical characteristics

Online supplemental table 4 shows regression coefficients for clinical characteristics and cg19693031 methylation, independent of HbA1c. After adjusting for HbA1c, diabetes duration, sex, pack years of smoking, and estimated cell type composition, higher baseline triglycerides and pulse rate were significantly ($p < 0.05$) associated with cg19693031 hypomethylation. In the final multivariable model, lower cg19693031 DNAm was significantly, independently associated only with higher pulse rate ($p = 0.009$).

Associations between cg19693031 methylation and longitudinal measures of clinical risk factors independent of HbA1c are shown in online supplemental table 5. After adjusting for HbA1c, diabetes duration, sex, pack years of smoking, and estimated cell type composition, the variables significantly associated with cg19693031 were total cholesterol, non-HDLc, triglycerides, pulse rate and natural log transformed albumin:creatinine ratio ($\ln(\text{ACR})$). After full adjustment for all other significant clinical factors, associations between cg19693031 and triglycerides, pulse rate, and $\ln(\text{ACR})$ remained significant (figure 3 and online supplemental table 5). For $\ln(\text{ACR})$, there was a marginal cg19693031 \times time interaction ($p = 0.07$) such that the association between cg19693031 DNAm and $\ln(\text{ACR})$ strengthened over time.

DISCUSSION

Our results confirm prior findings that hypomethylation of cg19693031 in *TXNIP* is cross-sectionally associated with higher HbA1c in type 1 diabetes. Additionally, we now extend those findings by demonstrating that cg19693031 hypomethylation is associated with consistently worse HbA1c over the subsequent 28 years. Furthermore, lower cg19693031 methylation was cross-sectionally associated with higher pulse rate independent of HbA1c, and longitudinally associated with triglycerides, pulse rate, and albumin:creatinine ratio (ACR) over 28 years, independently of HbA1c. These glycemia-independent risk factor associations suggest a more general role of *TXNIP* in metabolic control and vascular disease beyond its role in glucose metabolism. Finally, we observed cg19693031 methylation is influenced by variants in the *SLC2A1* locus, the gene encoding GLUT1, for the first time in a type 1 diabetes cohort. Our findings support further exploration into targeting *TXNIP* to improve glycemic control through its role in GLUT1-mediated glucose transport/homeostasis.

The follow-up period of our longitudinal analysis includes a time of rapid adoption of intensive diabetes therapy following the DCCT results in 1993,³⁷ which

Table 2 CpGs associated with longitudinal HbA1c at FDR of <20% in the EDC study

ID	Chr	Location	CpG position	Gene symbol	Location relative to gene	β per 5% methylation	SE	P value	bacon-adjusted FDR*
cg19693031	1	Open Sea	145 441 552	<i>TXNIP</i>	3'UTR	-0.202	0.0273	9.23E-13	<0.0001
cg12578588	19	Open Sea	18 132 275	n/a	Intergenic	-0.436	0.0807	1.16E-07	0.0230
cg02988288	1	Open Sea	145 440 445	<i>TXNIP</i>	Body	-0.437	0.0831	2.31E-07	0.0326
cg21566642	2	Island	233 284 661	n/a	Intergenic	-0.157	0.0313	7.22E-07	0.1233
cg14885762	17	N.Shore	75 446 450	<i>SEPT9</i>	TSS200	-0.426	0.0867	1.32E-06	0.1015
cg20772590	17	N.Shore	75 446 431	<i>SEPT9</i>	TSS200	-0.491	0.1002	1.41E-06	0.1015
cg05575921	5	N.Shore	373 378	<i>AHRR</i>	Body	-0.110	0.0226	1.48E-06	0.1015
cg01940273	2	Island	233 284 934	n/a	Intergenic	-0.228	0.0474	2.12E-06	0.1292
cg26974062	1	Open Sea	145 440 734	<i>TXNIP</i>	Body	-0.437	0.0934	3.88E-06	0.1793
cg18984002	17	Open Sea	36 876 514	<i>MLL76</i>	Body	-0.700	0.1502	4.23E-06	0.1793
cg25648203	5	Open Sea	395 444	<i>AHRR</i>	Body	-0.254	0.0544	4.26E-06	0.1793
cg04507446	16	N.Shore	422 157	<i>TMEM8A</i>	Body	-0.312	0.0669	4.48E-06	0.1793

Results of linear mixed models adjusted for type 1 diabetes duration, sex, pack years of smoking, estimated cell type composition variables, and plate/run indicator, well position, GCT bisulfite score, DNA extraction method, study visit of DNA collection, first two principal components of ancestry from genotyping arrays, and two surrogate variables from *sva*, sorted by p value in ascending order.

*Bolded row is significant at the Bonferroni-adjusted threshold $p < 7.3 \times 10^{-8}$.

CpG, 5'-cytosine-phosphate-guanine-3'; EDC, Epidemiology of Diabetes Complications; FDR, false discovery rate; n/a, not applicable; *TXNIP*, Thioredoxin-Interacting Protein.




Figure 2 Twenty-eight year longitudinal HbA1c by quartile of baseline cg19693031 DNA methylation in the Epidemiology of Diabetes Complications cohort. cg19693031 quartiles: Q1=0.3971–0.6801, Q2=0.6802–0.7393, Q3=0.7394–0.7912, and Q4=0.7913–0.9191.

is clearly reflected here in the decreasing trajectory of HbA1c after years 4–6 (corresponding to 1992–1994 and 1994–1996, respectively, for 98% of the cohort). As shown in figure 2, while there was a similar relative improvement in HbA1c regardless of cg19693031 methylation, in those with lower cg19693031 methylation, higher absolute HbA1c persisted. *TXNIP* is known to play a key role in regulating both insulin-independent (GLUT1) and insulin-dependent (GLUT4) glucose transport by promoting GLUT endocytosis under high-glucose conditions.³⁸ Our findings support the hypothesis that the association between *TXNIP* DNAm and HbA1c is primarily independent of insulin (ie, via GLUT1) by our identification of significant meQTLs for cg19693031 methylation in *SLC2A1*, as well as our observation that the association between *TXNIP* cg19693031 and HbA1c persisted despite intensification of insulin regimen over the follow-up period.

Our results are consistent with prior studies in the general population reporting cg19693031 as the differentially methylated CpG most strongly associated with type 2 diabetes, fasting blood glucose, and HbA1c.^{2–12} In DCCT/EDIC, the only other study reporting an EWAS of DNAm and HbA1c in type 1 diabetes to date, cg19693031 also had the strongest association with HbA1c.¹⁵ Our finding that cg19693031 DNAm remains consistently associated with HbA1c over the long term extends and solidifies the role of *TXNIP* DNAm in regulating glycemia in type 1 diabetes. We also identified 34 meQTLs in *SLC2A1/SLC2A1-AS1*, which we were able to externally validate in GoDMC, strongly supporting the hypothesis that *SLC2A1* is involved in epigenetic regulation of *TXNIP*. Intriguingly, in DCCT/EDIC, only one *trans*-meQTL on chromosome 16 was associated with cg19693031 DNAm. The differences in meQTLs between the two studies




Figure 3 Twenty-eight year longitudinal triglycerides (A), pulse rate (B), and ACR (natural log transformed) (C) by quartile of baseline cg19693031 DNA methylation in the EDC cohort. cg19693031 quartiles: Q1=0.3971–0.6801, Q2=0.6802–0.7393, Q3=0.7394–0.7912, and Q4=0.7913–0.9191. ACR, albumin:creatinine ratio.

could reflect differences between the two cohorts in genetic composition or exposure to other risk factors, as DCCT had key exclusion criteria, including hypertension, hypercholesterolemia, and advanced microvascular disease, while EDC had minimal exclusion criteria.³¹

Without DNAm measures prior to type 1 diabetes onset, we cannot definitively determine the direction of the cg19693031–HbA1c association. The association

between *TXNIP* DNAm and glycemia is not diabetes-specific, as the association has also been observed in the non-diabetes range of blood glucose.³⁹ Therefore, it is possible that exposures prior to type 1 diabetes onset (eg, during fetal development or early childhood), interact with genetic variants, such as *SLC2A1*, to influence *TXNIP* DNAm. While our MR analysis did not support a causal association between *TXNIP* DNAm and HbA1c, there is in vitro evidence that hyperglycemia induces changes in *TXNIP* DNAm.¹⁵ On the other hand, the role of *TXNIP* as a key glucose regulator and our observation that *TXNIP* hypomethylation is associated with sustained poor glycemic control over the long term suggests that it may also contribute to hyperglycemia. Thus, the association between glycemia and *TXNIP* DNAm may be bidirectional, where early hyperglycemia induces *TXNIP* hypomethylation, leading to impaired *TXNIP* function or reduced *TXNIP* expression which, in turn, impedes subsequent achievement of optimal glycemic control even with more intensive diabetes therapy.

Our observation of HbA1c-independent associations between *TXNIP* methylation and triglycerides, pulse rate, and ACR suggests a more general role for *TXNIP* methylation in metabolic control and vascular pathogenesis beyond glucose regulation. Prior research in *TXNIP* knockout mice showed a similar association with higher resting heart rate due to significantly increased myocardial glucose uptake with *TXNIP* deletion.⁴⁰ *TXNIP* has also been shown to play a key role in angiogenesis in response to tissue injury via vascular endothelial growth function regulation.⁴¹ In epidemiological data, DCCT/EDIC found significant associations between cg19693031 DNAm eGFR decline over follow-up, adjusting for baseline, but not longitudinal, HbA1c.¹⁵ Though we did not observe a statistically significant association between methylation of cg19693031 in *TXNIP* and longitudinal eGFR in the current study, we did observe a strong association with ACR, suggesting a role for *TXNIP* DNAm in microvascular damage that is independent of HbA1c. All together, these findings support the need for more research into potential therapeutic targeting of *TXNIP* to reduce vascular complications in diabetes.

DNAm of cg21534330 in *CSNK1D*, the gene encoding CK1 δ , was also significantly associated with cross-sectional HbA1c in our study, but the association was driven by a small number of participants with both extreme low DNAm values and high HbA1c and not consistently maintained in longitudinal analyses. It may therefore be a spurious finding and should be interpreted with caution. Inhibition of CK1 δ has been shown to affect glucose homeostasis and metabolic regulation in animal models of obesity,⁴² so there is a plausible mechanism for the association between cg21534330 DNAm and HbA1c, but more research is needed to confirm this finding.

Our study has many strengths, including the use of data from a well-characterized, exclusively type 1 diabetes cohort with long-term follow-up to assess longitudinal HbA1c. The EDC cohort has been shown to be

epidemiologically representative of the childhood-onset type 1 diabetes population of Allegheny County, Pennsylvania.^{43,44} We have incorporated genotyping array data to assess meQTLs and validated them in a database of a large-scale meta-analysis of international cohorts and using GTEx. Limitations of our study include the use of whole blood for DNAm. We also used a standard method²⁷ to account for potential confounding by blood cell-type composition. The use of HbA1c as a measure of glycemic exposure has known limitations.⁴⁵ HbA1c represents the approximate average glucose exposure over the preceding 3 months. It captures both fasting and postprandial glucose levels; thus, it does not account for glucose variability and is also influenced by erythrocyte characteristics. Future research using continuous glucose monitoring could improve understanding of the *SLC2A1*–*TXNIP* relationship to glycemia in type 1 diabetes. Another limitation is the lack of long-term glucose exposure data prior to DNAm assessment. Finally, a further limitation is that the EDC cohort is 98% white, a result of the combination of the demographics of Allegheny County, Pennsylvania (<15% black/African-American), historically lower incidence of type 1 diabetes among black individuals,⁴⁶ and institutional/ structural conditions that have reduced research participation in non-white groups. Furthermore, glycation of hemoglobin has been shown to differ by race, with HbA1c overestimating true glucose exposure in black persons.⁴⁷ Thus, our results may not apply to more diverse populations, and more research in non-white populations is critically needed.

CONCLUSIONS

We have demonstrated that methylation of CpGs in *TXNIP* is associated with subsequent long-term HbA1c, as well as triglycerides, pulse rate, and ACR independently of HbA1c, for the first time in type 1 diabetes. While more research is needed to resolve the question of whether these relationships are causal, our findings nonetheless strengthen the potential for interventions targeting *TXNIP* to improve glycemic control, particularly through insulin-independent *SLC2A1*/GLUT1-mediated glucose regulation.

Acknowledgements We thank the Epidemiology of Diabetes Complications study participants and staff for their invaluable contributions and dedication to this research for over 30 years.

Contributors RGM and TJO designed the study. RGM, TJO, and TC contributed to acquisition of funding and data. SO-G oversaw methylation array processing. JCM performed the methylation data processing and quality control. RGM conducted the statistical analyses, drafted the manuscript, and is the guarantor of this work. RGM, JCM, SO-G, TJO, and TC interpreted the data. All authors edited and critically reviewed the manuscript for intellectual content and approved the final version.

Funding The parent EDC study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health (grant number R01-DK034818) and the Rossi Memorial Fund. The EDC DNA methylation sub-study is supported by the American Diabetes Association (grant number 1-19-JDF-109). The funding agencies were not involved in study design, data collection, data analysis, manuscript preparation or publication decisions.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by the University of Pittsburgh institutional review board (approval number 19040065). The participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The data analyzed in this study are available from the corresponding author upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Rachel G Miller <http://orcid.org/0000-0003-1845-8477>

REFERENCES

- Nathan DM. Realising the long-term promise of insulin therapy: the DCCT/EDIC study. *Diabetologia* 2021;64:1049–58.
- Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. *Nat Rev Endocrinol* 2017;13:385–99.
- Liu XS, Wu H, Ji X, et al. Editing DNA methylation in the mammalian genome. *Cell* 2016;167:e17:233–47.
- Chambers JC, Loh M, Lehne B, et al. Epigenome-Wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study. *Lancet Diabetes Endocrinol* 2015;3:526–34.
- Kulkarni H, Kos MZ, Neary J, et al. Novel epigenetic determinants of type 2 diabetes in Mexican-American families. *Hum Mol Genet* 2015;24:5330–44.
- Xiang Y, Wang Z, Hui Q, et al. Dna methylation of TXNIP independently associated with inflammation and diabetes mellitus in twins. *Twin Res Hum Genet* 2021;24:273–80.
- Florath I, Butterbach K, Heiss J, et al. Type 2 diabetes and leucocyte DNA methylation: an epigenome-wide association study in over 1,500 older adults. *Diabetologia* 2016;59:130–8.
- Soriano-Tárraga C, Jiménez-Conde J, Giralt-Steinhauer E, et al. Epigenome-wide association study identifies TXNIP gene associated with type 2 diabetes mellitus and sustained hyperglycemia. *Hum Mol Genet* 2016;25:609–19.
- Walaszczyk E, Luijten M, Spijkerman AMW, et al. DNA methylation markers associated with type 2 diabetes, fasting glucose and HbA_{1c} levels: a systematic review and replication in a case-control sample of the Lifelines study. *Diabetologia* 2018;61:354–68.
- Mathur R, Hui Q, Huang Y, et al. Dna methylation markers of type 2 diabetes mellitus among male veterans with or without human immunodeficiency virus infection. *J Infect Dis* 2019;219:1959–62.
- Meeks KAC, Henneman P, Venema A, et al. Epigenome-Wide association study in whole blood on type 2 diabetes among sub-Saharan African individuals: findings from the RODAM study. *Int J Epidemiol* 2019;48:58–70.
- Juviniao-Quintero DL, Marioni RE, Ochoa-Rosales C, et al. Dna methylation of blood cells is associated with prevalent type 2 diabetes in a meta-analysis of four European cohorts. *Clin Epigenetics* 2021;13:40.
- Kim H, Bae JH, Park KS, et al. Dna methylation changes associated with type 2 diabetes and diabetic kidney disease in an East Asian population. *J Clin Endocrinol Metab* 2021;106:e3837–51.
- Wang Z, Peng H, Gao W, et al. Blood DNA methylation markers associated with type 2 diabetes, fasting glucose, and HbA_{1c} levels: an epigenome-wide association study in 316 adult twin pairs. *Genomics* 2021;113:4206–13.
- Chen Z, Miao F, Braffett BH, et al. Dna methylation mediates development of HbA_{1c}-associated complications in type 1 diabetes. *Nat Metab* 2020;2:744–62.
- The DCCT Research Group. The diabetes control and complications trial (DCCT). design and methodologic considerations for the feasibility phase. The DCCT Research Group. *Diabetes* 1986;35:530–45.
- Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh epidemiology of diabetes complications study II. *Diabetes* 1990;39:1116–24.
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988;16:1215.
- Moran S, Arribas C, Esteller M. Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. *Epigenomics* 2016;8:389–99.
- Aryee MJ, Jaffe AE, Corrada-Bravo H, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics* 2014;30:1363–9.
- Zhou W, Triche TJ, Laird PW, et al. Sesame: reducing artifactual detection of DNA methylation by Infinium BeadChips in genomic deletions. *Nucleic Acids Res* 2018;46:e123.
- Zhou W, Laird PW, Shen H. Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res* 2017;45:e22.
- Salem RM, Todd JN, Sandholm N, et al. Genome-Wide association study of diabetic kidney disease highlights biology involved in glomerular basement membrane collagen. *J Am Soc Nephrol* 2019;30:2000–16.
- Teschendorff AE, Zheng SC. Cell-Type deconvolution in epigenome-wide association studies: a review and recommendations. *Epigenomics* 2017;9:757–68.
- Salas LA, Koestler DC, Butler RA, et al. An optimized library for reference-based deconvolution of whole-blood biospecimens assayed using the Illumina HumanMethylationEPIC BeadArray. *Genome Biol* 2018;19:1–14.
- Koestler DC, Jones MJ, Usset J, et al. Improving cell mixture deconvolution by identifying optimal DNA methylation libraries (IDOL). *BMC Bioinformatics* 2016;17:1–21.
- Houseman EA, Accomando WP, Koestler DC, et al. Dna methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics* 2012;13:86.
- Prince CT, Becker DJ, Costacou T, et al. Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh epidemiology of diabetes complications study (EDC). *Diabetologia* 2007;50:2280–8.
- Leek J, Johnson W, Parker H. *Surrogate variable analysis*, 2021.
- van Iterson M, van Zwet EW, Heijmans BT. Controlling bias and inflation in epigenome- and transcriptome-wide association studies using the empirical null distribution. *Genome Biol* 2017;18:1–13.
- Miller RG, Costacou T, Orchard TJ. Risk factor modeling for cardiovascular disease in type 1 diabetes in the Pittsburgh epidemiology of diabetes complications (EDC) study: a comparison with the diabetes control and complications Trial/Epidemiology of diabetes interventions and complications study (DCCT/EDIC). *Diabetes* 2019;68:409–19.
- Miller RG, Orchard TJ, Onengut-Gumuscu S, et al. Heterogeneous long-term trajectories of glycaemic control in type 1 diabetes. *Diabet Med* 2021;38:e14545.
- Min JL, Hemani G, Hannon E, et al. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. *Nat Genet* 2021;53:1311–21.
- Boughton AP, Welch RP, Flickinger M, et al. LocusZoom.js: interactive and embeddable visualization of genetic association study results. *Bioinformatics* 2021;37:3017–8.
- Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenotype. *Life* 2018;7:e34408.
- Soranzo N, Sanna S, Wheeler E, et al. Common variants at 10 genomic loci influence hemoglobin A_{1c} levels via glycaemic and nonglycaemic pathways. *Diabetes* 2010;59:3229–39.
- Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial Research Group. *N Engl J Med* 1993;329:977–86.
- Alhawiti NM, Al Mahri S, Aziz MA, et al. Txn1p in metabolic regulation: physiological role and therapeutic outlook. *Curr Drug Targets* 2017;18:1095.

- 39 Tsai H-H, Shen C-Y, Ho C-C, *et al.* Interaction between a diabetes-related methylation site (TXNIP cg19693031) and variant (GLUT1 rs841853) on fasting blood glucose levels among non-diabetics. *J Transl Med* 2022;20:1–9.
- 40 Yoshioka J, Imahashi K, Gabel SA, *et al.* Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. *Circ Res* 2007;101:1328–38.
- 41 Dunn LL, Simpson PJL, Prosser HC, *et al.* A critical role for thioredoxin-interacting protein in diabetes-related impairment of angiogenesis. *Diabetes* 2014;63:675–87.
- 42 Cunningham PS, Ahern SA, Smith LC, *et al.* Targeting of the circadian clock via CK1 δ/ϵ to improve glucose homeostasis in obesity. *Sci Rep* 2016;6.
- 43 Wagener DK, Sacks JM, LaPorte RE, *et al.* The Pittsburgh study of insulin-dependent diabetes mellitus. risk for diabetes among relatives of IDDM. *Diabetes* 1982;31:136–44.
- 44 Miller RG, Secrest AM, Sharma RK, *et al.* Improvements in the life expectancy of type 1 diabetes: the Pittsburgh epidemiology of diabetes complications study cohort. *Diabetes* 2012;61:2987–92.
- 45 Beck RW, Connor CG, Mullen DM, *et al.* The Fallacy of Average: How Using HbA_{1c} Alone to Assess Glycemic Control Can Be Misleading. *Diabetes Care* 2017;40:994–9.
- 46 LaPorte RE, Tajima N, Dorman JS, *et al.* Differences between blacks and whites in the epidemiology of insulin-dependent diabetes mellitus in Allegheny County, Pennsylvania. *Am J Epidemiol* 1986;123:592–603.
- 47 Bergenstal RM, Gal RL, Connor CG, *et al.* Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. *Ann Intern Med* 2017;167:95–102.